Vinpocetine Sodium Chloride Injection

1. Pharmacological action This product has a selective effect on cerebral blood vessels. By increasing cerebral blood flow, it improves the oxygen supply to the brain. 2. Toxicological action No toxicological data for injection administration have been found yet. The following is the toxicity test data for oral administration. (1) Repeated administration: Rats were orally administered 5.25.125.625 mg/kg of this product for 5 consecutive weeks. The weight growth of the animals in the two high-dose groups was inhibited, the water intake of the animals increased, the weight of the liver and kidney increased, and the number of tiny lipid droplets in the zona cystica of the adrenal cortex increased; in the 625 mg/kg group, the urine and feces turned black, the weight of the thyroid and adrenal glands increased, and the thyroid follicular epithelium was hypertrophic, which may be caused by the metabolites of this product. The above changes recovered after stopping the drug. The non-toxic dose of this test is 25 mg/kg. Rats were orally administered 5.20 and 80 mg/kg of this product daily for 26 consecutive weeks. The animals in the high-dose group showed transient inhibition of body weight growth and increased liver weight. Male rats also showed mild swelling and degeneration of the renal tubular epithelium, but no abnormal changes were observed in blood biochemical indicators. Dogs were orally administered 5.25 mg/kg of this product daily for 6 consecutive months. No animal deaths were observed, and no abnormal changes were observed in blood biochemical examinations and histological examinations. (2) Reproductive toxicity: Rats were orally administered 25 to 125 mg/kg/day of this product before and after pregnancy. No abnormalities were observed in the reproductive capacity and fetal development of female rats, but animals in the high-dose group showed inhibition of body weight growth and increased liver, kidney and adrenal weights. During the period of organogenesis in rats, 5.25.125 mg/kg/day of this product was orally administered, and the high-dose group showed an increase in fetal mortality and developmental inhibition; during the period of organogenesis in rabbits, 1.5.25.125 mg/kg/day of this product was orally administered, and animals in the group administered with a dose of 5 mg/kg/day or above showed abortion. There were no abnormalities in the live offspring of both animals. No teratogenic effects were observed. The results of rat tests showed that this product can be secreted through breast milk. If this product must be used, breastfeeding should be stopped.

The main ingredient of this product is vinpocetine, and its chemical name is ethyl apovincamine-22-acetate. The chemical structure is: Molecular formula: C22H26N2O2 Molecular weight: 350.46

This product is a colorless clear liquid.

Improve various symptoms caused by sequelae of cerebral infarction, sequelae of cerebral hemorrhage, cerebral arteriosclerosis, etc.

Intravenous drip. The initial dose is 20 mg per day, which can be increased to 30 mg later depending on the condition. The daily dose can be divided into one or two slow intravenous drips.

1. Allergies: Sometimes rashes may occur, and occasionally allergic symptoms such as urticaria and itching may occur. If these symptoms occur, the drug should be discontinued. 2. Mental and nervous system: Sometimes headaches, heavy head, dizziness, occasional drowsiness, numbness of the lateral limbs, and increased weakness. 3. Digestive tract: Sometimes nausea and vomiting, and occasionally loss of appetite, abdominal pain, diarrhea and other symptoms. 4. Circulatory organs: Sometimes facial flushing, dizziness and other symptoms may occur. 5. Blood: Sometimes leukopenia may occur. 6. Liver: Sometimes S-GOT, S-GPT, γ-GTP may increase, and occasionally AL-P may increase. 7. Kidneys: Occasionally, blood urea nitrogen may increase.

1. It is contraindicated for those who are allergic to this product. 2. It is contraindicated for those in the acute stage of intracranial hemorrhage. 3. It is contraindicated for those with severe ischemic heart disease or severe arrhythmia.

Precautions for children: Not recommended. Precautions for pregnancy and lactation: Pregnant women or women who may be pregnant are prohibited. Lactating women should use with caution and should stop breastfeeding if necessary. Precautions for the elderly: Those with impaired liver and kidney function should reduce the dosage as appropriate.

Not yet clear.

Keep away from light, seal tightly, and store in a cool and dry place (10-20℃).

100ml: Vinpocetine 10mg and sodium chloride 0.9g

24 months

Liaoning Yifan Pharmaceutical Co., Ltd.

• Founded in:

  2011-05-05

• Address:

  No. 67 Xianghuai Road, Benxi Economic and Technological Development Zone

• Tax NO.:

  9121050057425945XH

• Registered Funds:

  10 million yuan

• Email:

  Log in to view